Clinical Scenario: A 73-Year-Old Patient With R/R FL Requires Treatment in the Third-Line Setting

Summary for Physicians:

Topic: Clinical Approach to an R/R FL Case in the Third-Line Setting

Key Points:

1. Initial Impressions:
   1. When evaluating a patient in the third-line setting, key clinical considerations include the following:
      1. Disease biology and pace of relapse (indolent vs more aggressive)
      2. Duration and quality of response to prior lines of therapy
      3. Presence of symptoms, comorbidities, and overall performance status
      4. Any prior exposure to specific agents (eg, anti-CD20 therapies, alkylating agents, or PI3K inhibitors)
2. Treatment Considerations:
   1. Treatment in the third-line setting would be personalized based on the following:
      1. Patient’s fitness and treatment goals
      2. Previous treatment responses and toxicities
      3. Current disease burden and symptomatology
   2. Options may include novel agents (eg, EZH2 inhibitors or bispecific antibodies), clinical trial enrollment, or cellular therapies in select cases.
   3. In some patients, retreatment with prior regimens may be appropriate if previous responses were durable and well tolerated.

Clinical Implication: A thoughtful, individualized approach is essential when managing R/R FL in the third-line setting. Reviewing disease course, patient status, and available therapies helps guide optimal treatment planning and ensures alignment with patient goals.